Who is sponsoring NCT05183386?

NCT05183386 is sponsored by University of Salamanca.

What drugs are being tested in NCT05183386?

Interventions in NCT05183386: dental socket regeneration.

What condition does NCT05183386 study?

NCT05183386 studies Alveolar Bone Loss.

Is NCT05183386 still recruiting?

NCT05183386 is currently completed. Last updated 11 January 2022.

Last reviewed 2022-01-11 · How we verify

NCT05183386

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Histological Outcome of the Use of Different Biomaterials for Fresh Socket Regeneration. A Split-mouth Design

Completed NA Last updated 11 January 2022

What this trial tests

NA trial testing dental socket regeneration in Alveolar Bone Loss in 30 participants. Completed in 1 January 2020.

Timeline

1 January 2014

Primary endpoint
1 January 2019

1 January 2020

Quick facts

Lead sponsor	University of Salamanca
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	1 January 2014
Primary completion	1 January 2019
Estimated completion	1 January 2020

Drugs / interventions tested

dental socket regeneration

Conditions studied

Alveolar Bone Loss — all drugs for Alveolar Bone Loss →

Sponsor

University of Salamanca

Who can join

Adults 18 to 75, any sex, with Alveolar Bone Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose: The aim of this study was to analyze the quality of bone regeneration in fresh sockets using four different materials and at different times points. Materials and Methods: A split-mouth clinical trial was designed to evaluate the histological and histomorphometrical characteristics of fresh sockets from 30 patients. One socket per patient will healed spontaneously (control) and, at least, one fresh socket, will be grafted with platelet-rich growth factor (PRGF), PRGF+autologous bone, autologous bone or PRGF+demineralized freeze dried bone allograft (DFDBA). The day of the implant placement, biopsies will be taken at different time points divided into three assessment groups: short duration (2-4 months), intermediate duration (5-6 months) and long duration (7-12 months). The histologic findings will be assessed to quantify the trabeculae pattern, the degree of mineralization and the quality of bone regeneration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Alveolar Bone Loss

Currently open trials in the same condition.

NCT07508033 — Evaluation of Stem Cell Exosomes Versus Platelet-Rich Fibrin in Tooth Extraction Socket Healing · Phase 1, PHASE2 · recruiting
NCT07375004 — Injectable PRF in Non-Surgical Periodontal Treatment · NA · active not recruiting
NCT07449806 — Assessment of Labial Plate Thickness After Immediate Implant Placement Using Two Different Xenografts in the Esthetic Zo · NA · recruiting
NCT07419269 — Comparison of Customized Allogenic Versus Autogenous Bone Block Graft for Alveolar Ridge Augmentation · NA · recruiting
NCT06887582 — Crestal Sinus Lifting in Periodontally-Compromised Patients Utilizing Autologous Dentin Graft · NA · active not recruiting

Other University of Salamanca trials

Trials by the same sponsor.

NCT07359495 — Multicomponent Training and Muscle Quality in Older Women · NA · not yet recruiting
NCT07286539 — Precision Physical Exercise for Personalized Onco-Hematology. · NA · not yet recruiting
NCT07387770 — Muscle Deterioration in Hospitalized Cancer Patient · NA · not yet recruiting
NCT07387757 — Exergames in Mental Health · NA · not yet recruiting
NCT07333768 — EQUISOCK: New Antiequine · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05183386 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Salamanca
Last refreshed: 11 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05183386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing